{"gene":"TNFRSF21","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1998,"finding":"DR6 (TNFRSF21) is a type I transmembrane receptor with four extracellular cysteine-rich motifs and a cytoplasmic death domain. Ectopic expression induces apoptosis and activation of both NF-κB and JNK. DR6 interacts with TRADD (the adaptor previously shown to associate with TNFR1), identified by co-immunoprecipitation.","method":"Co-immunoprecipitation, ectopic expression in mammalian cells, apoptosis assays, NF-κB and JNK reporter assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal interaction with TRADD shown by Co-IP, functional apoptosis/NF-κB/JNK assays in single study","pmids":["9714541"],"is_preprint":false},{"year":2001,"finding":"DR6-mediated apoptosis is inhibited by Bcl-2, Bcl-xL, and survivin, but a dominant-negative FADD mutant failed to protect against DR6-induced apoptosis, indicating DR6 induces apoptosis via a FADD-independent mechanism. TNF-alpha induces DR6 mRNA and protein expression through NF-κB activation.","method":"Dominant-negative FADD co-expression, Bcl-2/Bcl-xL overexpression rescue assays, TNF-alpha treatment with NF-κB inhibitors, RT-PCR and western blot","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined pathway placement (FADD-independent), NF-κB-dependent transcriptional regulation, single lab with multiple orthogonal methods","pmids":["11753679"],"is_preprint":false},{"year":2001,"finding":"DR6 is highly expressed in resting T cells and downregulated upon activation. DR6-deficient mice show hyperproliferation of CD4+ T cells in response to TCR stimulation and protein antigen challenge, enhanced IL-2 responsiveness, increased CD28 and decreased CTLA-4 expression, and enhanced Th2 cytokine production associated with increased nuclear NF-ATc. DR6 thus functions as a negative regulatory receptor for CD4+ T cell activation.","method":"DR6 knockout mouse generation, T cell proliferation assays, cytokine measurement, flow cytometry, transcription factor nuclear localization assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse with specific T cell phenotype, multiple orthogonal readouts including proliferation, cytokine profiling, and signaling molecule quantification","pmids":["11485735"],"is_preprint":false},{"year":2009,"finding":"DR6 is broadly expressed by developing neurons and is required for normal cell body death (via caspase 3) and axonal pruning (via caspase 6) after trophic-factor deprivation. Trophic-factor deprivation triggers BACE-dependent shedding of surface APP, releasing an N-terminal APP fragment (N-APP) that binds DR6 and triggers degeneration. Loss- and gain-of-function studies in vitro and in vivo, plus a common neuromuscular junction phenotype in APP and DR6 mutant mice, support this model.","method":"Loss-of-function (DR6 KO mice, siRNA), gain-of-function, binding assays (N-APP/DR6 interaction), caspase activity assays, in vivo axon pruning/neuron death assays, genetic epistasis (NMJ phenotype in double mutant mice)","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including KO mouse, in vitro binding, caspase-specific assays, and genetic epistasis; replicated in multiple experimental systems","pmids":["19225519"],"is_preprint":false},{"year":2011,"finding":"Crystal structure of the extracellular cysteine-rich region of DR6 resolved to 2.2 Å, showing four cysteine-rich domains (CRDs) arranged in a rod-like structure with DR6-specific surface patches responsible for ligand recognition.","method":"X-ray crystallography of recombinant DR6 extracellular domain","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure at 2.2 Å resolution, single study but rigorous structural method","pmids":["21463639"],"is_preprint":false},{"year":2012,"finding":"DR6 and TROY (TNFRSF19) interact both genetically and physically, are required for VEGF-mediated JNK activation and human brain endothelial sprouting in vitro, and regulate CNS-specific angiogenesis and blood-brain barrier formation. DR6 and TROY are downstream target genes of Wnt/β-catenin signaling in brain endothelium.","method":"Co-immunoprecipitation (DR6/TROY physical interaction), zebrafish and mouse genetic knockouts, in vitro endothelial sprouting assays, JNK activity assays, gene expression profiling","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction demonstrated, genetic epistasis in two model organisms, in vitro functional assays with defined signaling readout","pmids":["22340501"],"is_preprint":false},{"year":2013,"finding":"DR6 binds p75NTR and forms a signaling complex responsible for Aβ-induced cortical neuron death. Cortical neurons from DR6 or p75NTR null mice are resistant to Aβ-induced neurotoxicity. Blocking DR6/p75NTR interaction with anti-DR6 antibodies or dominant-negative DR6 (lacking the cytoplasmic death domain) attenuates caspase 3 activation and cell death.","method":"Co-immunoprecipitation (DR6/p75NTR complex), DR6 and p75NTR null mouse neurons, dominant-negative DR6 construct, anti-DR6 blocking antibodies, caspase 3 activity assays","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, two independent KO mouse lines, dominant-negative rescue, multiple orthogonal functional assays in single study","pmids":["23559013"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of DR6 ectodomain in complex with the E2 domain of APP, showing the structural basis of APP binding to DR6 and supporting a model in which APP induces DR6 dimerization and activation at the cell surface.","method":"X-ray crystallography of DR6 ectodomain/APP-E2 complex","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure of the complex providing direct structural evidence for the interaction mechanism, single study","pmids":["25838500"],"is_preprint":false},{"year":2015,"finding":"miR-210 targets the 3'-UTR of DR6 to inhibit its expression (confirmed by luciferase assay), thereby inhibiting NF-κB pathway activation and reducing inflammatory cytokine production and apoptosis in chondrocytes.","method":"Luciferase reporter assay (miR-210 targeting DR6 3'-UTR), miR-210 mimic/siDR6 transfection, NF-κB pathway activation assays, cytokine ELISA","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — luciferase reporter validates direct miRNA targeting, NF-κB pathway readout provided, single lab","pmids":["26244598"],"is_preprint":false},{"year":2016,"finding":"DR6 knockdown in mouse B16 melanoma cells suppresses tumor angiogenesis in vivo by inhibiting IL-6 secretion, which in turn reduces VEGF-A, PDGF-β, VEGF-D, and PDGFR-α expression. DR6-dependent angiogenesis proceeds through IL-6/P38 MAPK and IL-6/STAT3 pathways.","method":"DR6 knockdown in B16 cells, xenograft tumor model, cytokine profiling, pathway inhibitor assays (P38 MAPK, STAT3)","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo xenograft with mechanistic pathway dissection, single lab","pmids":["26950598"],"is_preprint":false},{"year":2018,"finding":"Neuronal DR6 is cleaved by ADAM10, releasing a soluble DR6 ectodomain (sDR6) that acts in a non-cell-autonomous (paracrine) manner to reduce Schwann cell proliferation and myelination. This function is independent of DR6's cytoplasmic death domain. The sDR6 ectodomain alone was sufficient to rescue the precocious myelination phenotype observed in DR6 KO mice.","method":"DR6 KO mice, in vitro myelination assay, ADAM10 cleavage identification (proteomics/biochemistry), sDR6 rescue experiment, death domain deletion construct","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse phenotype, identification of ADAM10 as sheddase, domain deletion construct, and sDR6 rescue in a single study with multiple orthogonal methods","pmids":["29459438"],"is_preprint":false},{"year":2019,"finding":"DR6, but not p75NTR, is required for transition into the catastrophic phase of axon degeneration in response to conditioned media from degenerating axons following trophic withdrawal. DR6 acts downstream of spheroid rupture and is calpain-dependent in this process, but is not required for intra-axonal calcium flux, spheroid formation, or spheroid rupture.","method":"DR6 KO mouse neurons, conditioned media transfer assay, live imaging of axon degeneration phases, calpain inhibitor assays","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — DR6 KO neurons with defined phased degeneration assay, single lab","pmids":["31628183"],"is_preprint":false},{"year":2020,"finding":"APP and TNFRSF21 interact at the protein level (confirmed by Co-IP) in AD model mice. TNFRSF21 knockdown reduces APP expression and decreases neuroinflammation (TNF-α, IL-5, IFN-γ levels) and neuronal apoptosis in transgenic AD mice.","method":"Co-immunoprecipitation, TNFRSF21 knockdown in vitro, ELISA for inflammatory cytokines, flow cytometry for apoptosis, immunofluorescence","journal":"European journal of pharmaceutical sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP confirms interaction, knockdown with functional inflammatory readouts, single lab","pmids":["33075465"],"is_preprint":false},{"year":2021,"finding":"APP expressed on tumor cells binds DR6 on vascular endothelial cells to initiate the necroptosis pathway, leading to endothelial cell death and tumor cell extravasation/metastasis. A peptidomimetic inhibitor of DR6/APP interaction (PEG-tAHP-DRI, KD = 51.12 nM) blocked TC-induced EC necroptosis in vitro and anti-hematogenous metastasis in multiple mouse models.","method":"Phage display-derived peptidomimetic binding assay (KD measurement), in vitro necroptosis assay, multiple in vivo metastatic mouse models (B16F10, 4T1, CT26)","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantified binding affinity, multiple in vivo models confirm necroptosis pathway activation, single lab","pmids":["34105277"],"is_preprint":false},{"year":2024,"finding":"Suppression of endothelial DR6 results in blood-brain barrier malfunction in the presence of Aβ oligomers, while DR6 overexpression in brain endothelial cells increases BBB functional proteins through activation of Wnt/β-catenin and JNK pathways and rescues BBB dysfunction in vitro.","method":"DR6 knockdown/overexpression in cultured brain endothelial cells, Aβ25-35 oligomer treatment, western blot for BBB functional proteins and pathway activation (Wnt/β-catenin, JNK), in vitro BBB permeability assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with defined signaling pathway readouts, single lab","pmids":["38609388"],"is_preprint":false},{"year":2024,"finding":"DR6 knockdown in colorectal cancer cells reduces AKT and NF-κB phosphorylation, and treatment with AKT activator SC79 rescues the inhibitory effects of DR6 knockdown on proliferation, migration, invasion, and stemness, establishing DR6 as an upstream activator of the AKT/NF-κB pathway in CRC.","method":"DR6 knockdown/overexpression, CCK-8 proliferation assay, transwell assays, sphere-forming assays, western blot for p-AKT and p-NF-κB, AKT activator rescue experiment, nude mouse xenograft","journal":"Biochemical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis rescue with SC79 places DR6 upstream of AKT/NF-κB, in vivo xenograft confirmation, single lab","pmids":["38478147"],"is_preprint":false},{"year":2024,"finding":"RBP4 (retinol binding protein 4) was identified as an antagonistic ligand of DR6. RBP4 drives DR6 dimerization on the plasma membrane via an extracellular intrinsically disordered region, preventing DR6 pro-degenerative heterointeractions and neurodegenerative processes. DR6 homodimerization is Ca2+-sensitive and depends on the extracellular intrinsically disordered region.","method":"Single-molecule photobleaching, single-receptor tracking, RBP4-DR6 binding characterization, domain deletion/mutation analysis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single-molecule methods are rigorous, but preprint and single lab without independent replication","pmids":[],"is_preprint":true},{"year":2025,"finding":"TNFRSF21 promotes necroptosis of vascular endothelial cells in sepsis by upregulating RIPK3 and phospho-MLKL (necrosome components). shTNFRSF21 inhibited necrosome (RIPK3/p-MLKL) formation in septic vascular endothelial cells, improved vascular leakage in septic rats, and prolonged survival.","method":"shTNFRSF21 knockdown, western blot for RIPK3/p-MLKL, CLP and LPS sepsis models in vivo, vascular leakage assays, necroptosis inhibitor treatment","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo sepsis model with defined pathway (RIPK1/RIPK3/MLKL necrosome), multiple readouts, single lab","pmids":["42020785"],"is_preprint":false},{"year":2026,"finding":"TNFRSF21 interacts with APP (confirmed by immunoprecipitation) in keratinocytes and regulates epithelial keratinization: TNFRSF21 knockdown downregulates KRT8, KRT18, and Claudin-1, while overexpression upregulates them and accelerates wound healing in a mouse model.","method":"Co-immunoprecipitation (TNFRSF21/APP interaction), gene knockdown and overexpression in keratinocytes, bulk RNA-seq, PPI analysis, full-thickness dorsal skin wound mouse model, immunostaining","journal":"Frontiers in bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirms interaction, KD/OE with defined keratinization phenotype, in vivo wound model, single lab","pmids":["41914294"],"is_preprint":false},{"year":2002,"finding":"Transfer of DR6 KO T cells into allogeneic recipients accelerates onset and increases severity of acute graft-versus-host disease, demonstrating that DR6 serves as a negative regulatory molecule in T cell immune responses in vivo. Enhanced activation and expansion of DR6 KO CD4+ and CD8+ T cells was observed.","method":"Adoptive transfer of DR6 KO T cells in parent-to-F1 GVHD model, histopathological analysis, T cell expansion quantification","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo adoptive transfer with defined cellular and histopathological phenotype, single lab","pmids":["12244201"],"is_preprint":false},{"year":2013,"finding":"DR6 promotes motor neuron death in ALS through activation of the caspase 3 signaling pathway. Blocking DR6 with antagonist antibody 5D10 promotes motor neuron survival via activation of Akt phosphorylation and inhibition of caspase 3, in growth factor withdrawal, arsenite treatment, and SOD1(G93A) astrocyte co-culture models.","method":"DR6 antagonist antibody treatment, caspase 3 activity assays, Akt phosphorylation western blot, in vitro motor neuron survival assays, SOD1(G93A) transgenic mouse treatment","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro stress models plus in vivo transgenic mouse, defined caspase 3/Akt pathway, single lab","pmids":["24113175"],"is_preprint":false}],"current_model":"TNFRSF21/DR6 is a death domain-containing TNF receptor superfamily member that functions as a context-dependent signaling hub: its extracellular domain binds APP (N-terminal fragment) and RBP4 to regulate neuronal axon pruning and cell body death via caspase 6 and caspase 3 respectively, forms a complex with p75NTR to mediate Aβ-induced neurotoxicity, is shed by ADAM10 to generate a soluble ectodomain that non-cell-autonomously controls Schwann cell proliferation/myelination, activates JNK and NF-κB signaling to regulate CNS angiogenesis/BBB integrity (partnering with TROY downstream of Wnt/β-catenin), acts as a negative regulator of T cell activation (limiting CD4+ proliferation and Th2 cytokine responses), promotes tumor angiogenesis through IL-6/STAT3/P38 MAPK pathways, drives necroptosis (RIPK3/p-MLKL) in vascular endothelial cells during sepsis, and activates the AKT/NF-κB pro-survival pathway in cancer cells."},"narrative":{"mechanistic_narrative":"TNFRSF21 (DR6) is a type I transmembrane death-domain receptor of the TNF receptor superfamily that acts as a context-dependent signaling hub coupling extracellular ligand engagement to apoptosis, inflammation, and developmental remodeling [PMID:9714541, PMID:19225519]. Its ectodomain comprises four cysteine-rich domains arranged in a rod-like structure with receptor-specific surface patches for ligand recognition [PMID:21463639], and it is activated at the cell surface by ligand-induced dimerization: an N-terminal fragment of APP binds the DR6 ectodomain and drives dimerization [PMID:19225519, PMID:25838500], while RBP4 acts as an antagonistic ligand that forces a non-productive Ca2+-sensitive homodimer and blocks pro-degenerative heterointeractions. Engaged DR6 signals through a FADD-independent route to activate NF-κB and JNK and to trigger apoptosis [PMID:9714541, PMID:11753679]; in developing neurons it executes trophic-deprivation degeneration by directing caspase-3-mediated cell-body death and caspase-6-mediated axon pruning, acting downstream of axonal spheroid rupture in a calpain-dependent manner [PMID:19225519, PMID:31628183]. DR6 partners with p75NTR to mediate Aβ-induced cortical neuron death [PMID:23559013] and with TROY downstream of Wnt/β-catenin to drive VEGF-dependent JNK activation, CNS angiogenesis, and blood-brain-barrier formation [PMID:22340501, PMID:38609388]. ADAM10 sheds the receptor to release a soluble ectodomain that acts non-cell-autonomously to restrain Schwann cell proliferation and myelination, independent of the cytoplasmic death domain [PMID:29459438]. In the immune system DR6 is a negative regulator of CD4+ T cell activation, limiting proliferation and Th2 cytokine responses and constraining graft-versus-host disease [PMID:11485735, PMID:12244201]. In pathological vascular and tumor settings it promotes endothelial necroptosis via RIPK3/p-MLKL and tumor angiogenesis through IL-6/STAT3/p38 MAPK signaling [PMID:34105277, PMID:42020785, PMID:26950598], and in carcinoma cells it activates an AKT/NF-κB pro-survival program [PMID:38478147].","teleology":[{"year":1998,"claim":"Established DR6 as a death-domain TNFR superfamily receptor that couples to canonical inflammatory and stress signaling, answering what kind of receptor this orphan was.","evidence":"Co-IP, ectopic expression and reporter assays in mammalian cells","pmids":["9714541"],"confidence":"Medium","gaps":["No physiological ligand identified","TRADD interaction not placed in a downstream effector pathway"]},{"year":2001,"claim":"Defined the apoptotic wiring of DR6 as FADD-independent and showed its expression is induced by TNF-α via NF-κB, clarifying both how it kills and how it is transcriptionally controlled.","evidence":"Dominant-negative FADD, Bcl-2/Bcl-xL rescue, NF-κB inhibitor and RT-PCR/western assays","pmids":["11753679"],"confidence":"Medium","gaps":["Identity of the FADD-independent adaptor unresolved","Apoptotic mechanism studied only in overexpression"]},{"year":2001,"claim":"Revealed an unanticipated immunological role: DR6 negatively regulates CD4+ T cell activation, expanding its function beyond apoptosis.","evidence":"DR6 KO mouse, proliferation/cytokine/transcription-factor assays","pmids":["11485735"],"confidence":"High","gaps":["Ligand mediating T cell suppression not defined","Intracellular signaling linking DR6 to NF-ATc not mapped"]},{"year":2002,"claim":"Confirmed the negative-regulatory role of DR6 in vivo, showing loss accelerates graft-versus-host disease.","evidence":"Adoptive transfer of DR6 KO T cells in parent-to-F1 GVHD model","pmids":["12244201"],"confidence":"Medium","gaps":["Cell-intrinsic versus extrinsic basis of the phenotype not separated","No ligand identified"]},{"year":2009,"claim":"Identified N-APP as a DR6 ligand and assigned DR6 distinct caspase routes for cell-body death (caspase 3) versus axon pruning (caspase 6) during trophic deprivation, providing the first ligand and developmental mechanism.","evidence":"DR6 KO/siRNA, binding assays, caspase-specific assays, NMJ genetic epistasis with APP mutants","pmids":["19225519"],"confidence":"High","gaps":["Mechanism segregating caspase-3 vs caspase-6 outputs unknown","Proximal cytoplasmic signaling adaptor undefined"]},{"year":2011,"claim":"Provided the structural framework for DR6 ligand recognition by resolving its four-CRD ectodomain.","evidence":"X-ray crystallography of recombinant DR6 ectodomain at 2.2 Å","pmids":["21463639"],"confidence":"High","gaps":["No ligand bound in this structure","Activation-associated conformational changes not captured"]},{"year":2012,"claim":"Placed DR6 in a TROY-containing complex downstream of Wnt/β-catenin that drives CNS angiogenesis and BBB formation via VEGF-dependent JNK, defining a developmental vascular function.","evidence":"Co-IP, zebrafish and mouse knockouts, endothelial sprouting and JNK assays, expression profiling","pmids":["22340501"],"confidence":"High","gaps":["Ligand triggering endothelial DR6/TROY signaling unknown","Stoichiometry of the DR6/TROY complex undefined"]},{"year":2013,"claim":"Showed DR6 forms a complex with p75NTR to mediate Aβ-induced cortical neuron death, linking it to amyloid neurotoxicity.","evidence":"Reciprocal Co-IP, DR6 and p75NTR null neurons, dominant-negative and blocking antibody, caspase 3 assays","pmids":["23559013"],"confidence":"High","gaps":["Whether Aβ binds DR6 directly not established","Relationship between p75NTR and APP ligand pathways unclear"]},{"year":2013,"claim":"Extended DR6-driven death to motor neurons in ALS and showed antagonist antibody promotes survival via Akt/caspase-3, indicating therapeutic tractability.","evidence":"Antagonist antibody 5D10, caspase 3 and Akt assays, multiple stress models and SOD1(G93A) mice","pmids":["24113175"],"confidence":"Medium","gaps":["Endogenous ligand in ALS models not identified","Antibody mechanism of action not structurally defined"]},{"year":2015,"claim":"Defined the structural basis of APP-induced activation by resolving the DR6 ectodomain/APP-E2 complex and supporting a dimerization model.","evidence":"X-ray crystallography of DR6 ectodomain/APP-E2 complex","pmids":["25838500"],"confidence":"High","gaps":["Higher-order receptor clustering not visualized","Coupling of dimerization to cytoplasmic signaling not shown structurally"]},{"year":2015,"claim":"Identified miR-210 as a post-transcriptional repressor of DR6 that dampens NF-κB-driven inflammation, adding a regulatory input layer.","evidence":"Luciferase 3'-UTR reporter, miR-210 mimic/siDR6, NF-κB and cytokine assays in chondrocytes","pmids":["26244598"],"confidence":"Medium","gaps":["Generality of miR-210 control beyond chondrocytes untested","In vivo relevance not demonstrated"]},{"year":2016,"claim":"Linked DR6 to tumor angiogenesis through IL-6/STAT3 and IL-6/p38 MAPK control of pro-angiogenic factors.","evidence":"DR6 knockdown in B16 cells, xenograft, cytokine profiling, pathway inhibitors","pmids":["26950598"],"confidence":"Medium","gaps":["Receptor-proximal events upstream of IL-6 not defined","Single tumor model"]},{"year":2018,"claim":"Revealed a non-cell-autonomous mechanism: ADAM10 sheds DR6 to release a soluble ectodomain that restrains Schwann cell myelination independent of the death domain.","evidence":"DR6 KO mice, ADAM10 cleavage mapping, sDR6 rescue and death-domain deletion construct, myelination assays","pmids":["29459438"],"confidence":"High","gaps":["Receptor/target of sDR6 on Schwann cells unknown","Regulation of ADAM10 cleavage not defined"]},{"year":2019,"claim":"Positioned DR6 at the catastrophic transition of axon degeneration, downstream of spheroid rupture and calpain-dependent, refining its temporal role.","evidence":"DR6 KO neurons, conditioned-media transfer, live imaging, calpain inhibitors","pmids":["31628183"],"confidence":"Medium","gaps":["Diffusible factor in conditioned media not identified","Link between calpain and DR6 activation unresolved"]},{"year":2020,"claim":"Reinforced DR6/APP interaction and showed DR6 knockdown reduces APP expression, neuroinflammation, and apoptosis in AD model mice.","evidence":"Co-IP, knockdown, cytokine ELISA, apoptosis flow cytometry","pmids":["33075465"],"confidence":"Medium","gaps":["Directionality of DR6-APP regulation not mechanistically resolved","Single AD model"]},{"year":2021,"claim":"Demonstrated tumor-cell APP engages endothelial DR6 to trigger necroptosis enabling metastasis, and that blocking the interaction is anti-metastatic.","evidence":"Peptidomimetic binding (KD 51 nM), in vitro necroptosis, multiple metastasis mouse models","pmids":["34105277"],"confidence":"Medium","gaps":["Mechanism linking DR6 to RIPK3/MLKL necrosome not detailed here","Single lab"]},{"year":2024,"claim":"Showed endothelial DR6 maintains BBB integrity against Aβ oligomers through Wnt/β-catenin and JNK, connecting its vascular and amyloid roles.","evidence":"DR6 knockdown/overexpression in brain endothelial cells, Aβ treatment, pathway western blots, permeability assay","pmids":["38609388"],"confidence":"Medium","gaps":["In vivo BBB confirmation absent","Ligand driving protective signaling unknown"]},{"year":2024,"claim":"Established DR6 as an upstream activator of AKT/NF-κB driving proliferation, invasion, and stemness in colorectal cancer.","evidence":"Knockdown/overexpression, SC79 rescue, functional assays, xenograft","pmids":["38478147"],"confidence":"Medium","gaps":["Receptor-proximal coupling to AKT undefined","Ligand in CRC context unknown"]},{"year":2024,"claim":"Identified RBP4 as an antagonistic ligand that drives Ca2+-sensitive DR6 homodimerization via an extracellular disordered region to block pro-degenerative heterointeractions, reframing dimerization state as the activity switch.","evidence":"Single-molecule photobleaching, single-receptor tracking, domain mutation analysis (preprint)","pmids":[],"confidence":"Medium","gaps":["Preprint, single lab, not independently replicated","In vivo neuroprotection by RBP4 not shown"]},{"year":2025,"claim":"Showed TNFRSF21 promotes endothelial necroptosis in sepsis by upregulating the RIPK3/p-MLKL necrosome, extending its necroptotic role to systemic vascular injury.","evidence":"shTNFRSF21, RIPK3/p-MLKL western blots, CLP and LPS sepsis models, survival/leakage assays","pmids":["42020785"],"confidence":"Medium","gaps":["Molecular link from DR6 to necrosome assembly not defined","Activating ligand in sepsis unknown"]},{"year":2026,"claim":"Revealed a non-neuronal epithelial function: TNFRSF21 interacts with APP and regulates keratinization genes and wound healing.","evidence":"Co-IP, knockdown/overexpression in keratinocytes, RNA-seq, wound-healing mouse model","pmids":["41914294"],"confidence":"Medium","gaps":["Signaling pathway linking DR6 to keratin genes not mapped","Single lab"]},{"year":null,"claim":"How ligand-driven dimerization state (productive APP-induced vs antagonistic RBP4-induced) is decoded into divergent outputs—apoptosis, necroptosis, NF-κB/JNK, AKT survival—through a defined cytoplasmic adaptor remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["FADD-independent proximal adaptor unidentified","Mechanism selecting caspase-3 vs caspase-6 vs RIPK3 outputs unknown","No unified model reconciling pro-death and pro-survival roles across cell types"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,6,7]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[3,7,16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,10,16]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,7,10,16]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,6,13,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,9,14,15]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,5,10]}],"complexes":["DR6/p75NTR signaling complex","DR6/TROY complex"],"partners":["APP","TRADD","P75NTR","TROY","RBP4","ADAM10"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75509","full_name":"Tumor necrosis factor receptor superfamily member 21","aliases":["Death receptor 6"],"length_aa":655,"mass_kda":71.8,"function":"Promotes apoptosis, possibly via a pathway that involves the activation of NF-kappa-B. Can also promote apoptosis mediated by BAX and by the release of cytochrome c from the mitochondria into the cytoplasm. Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP). Negatively regulates oligodendrocyte survival, maturation and myelination. Plays a role in signaling cascades triggered by stimulation of T-cell receptors, in the adaptive immune response and in the regulation of T-cell differentiation and proliferation. Negatively regulates T-cell responses and the release of cytokines such as IL4, IL5, IL10, IL13 and IFNG by Th2 cells. Negatively regulates the production of IgG, IgM and IgM in response to antigens. May inhibit the activation of JNK in response to T-cell stimulation. Also acts as a regulator of pyroptosis: recruits CASP8 in response to reactive oxygen species (ROS) and subsequent oxidation, leading to activation of GSDMC (PubMed:34012073)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/O75509/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF21","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF21","total_profiled":1310},"omim":[{"mim_id":"614436","title":"CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2P; CMT2P","url":"https://www.omim.org/entry/614436"},{"mim_id":"610933","title":"LEUCINE-RICH REPEAT- AND STERILE ALPHA MOTIF-CONTAINING 1; LRSAM1","url":"https://www.omim.org/entry/610933"},{"mim_id":"605732","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 21; TNFRSF21","url":"https://www.omim.org/entry/605732"},{"mim_id":"160700","title":"MYOPIA 2, AUTOSOMAL DOMINANT; MYP2","url":"https://www.omim.org/entry/160700"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":108.8},{"tissue":"urinary bladder","ntpm":138.2}],"url":"https://www.proteinatlas.org/search/TNFRSF21"},"hgnc":{"alias_symbol":["DR6","CD358"],"prev_symbol":[]},"alphafold":{"accession":"O75509","domains":[{"cath_id":"2.10.50.10","chopping":"53-133","consensus_level":"medium","plddt":96.7899,"start":53,"end":133},{"cath_id":"2.10.50.10","chopping":"138-213","consensus_level":"high","plddt":96.5709,"start":138,"end":213},{"cath_id":"1.10.533.10","chopping":"404-509","consensus_level":"high","plddt":83.2867,"start":404,"end":509},{"cath_id":"1.10.533.10","chopping":"580-654","consensus_level":"high","plddt":87.3916,"start":580,"end":654}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75509","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75509-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75509-F1-predicted_aligned_error_v6.png","plddt_mean":68.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF21","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF21"},"sequence":{"accession":"O75509","fasta_url":"https://rest.uniprot.org/uniprotkb/O75509.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75509/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75509"}},"corpus_meta":[{"pmid":"19225519","id":"PMC_19225519","title":"APP binds DR6 to trigger axon pruning and neuron death via distinct caspases.","date":"2009","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/19225519","citation_count":817,"is_preprint":false},{"pmid":"6980419","id":"PMC_6980419","title":"Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+.","date":"1982","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6980419","citation_count":331,"is_preprint":false},{"pmid":"9714541","id":"PMC_9714541","title":"Identification and functional characterization of DR6, a novel death domain-containing TNF receptor.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9714541","citation_count":229,"is_preprint":false},{"pmid":"22340501","id":"PMC_22340501","title":"Death receptors DR6 and TROY regulate brain vascular development.","date":"2012","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/22340501","citation_count":108,"is_preprint":false},{"pmid":"26244598","id":"PMC_26244598","title":"MiR-210 inhibits NF-κB signaling pathway by targeting DR6 in osteoarthritis.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26244598","citation_count":97,"is_preprint":false},{"pmid":"7860360","id":"PMC_7860360","title":"Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype.","date":"1994","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7860360","citation_count":86,"is_preprint":false},{"pmid":"11753679","id":"PMC_11753679","title":"Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11753679","citation_count":80,"is_preprint":false},{"pmid":"11298540","id":"PMC_11298540","title":"Increased frequency of HLA-DR6 allele in Italian patients with hepatitis C virus-associated oral lichen planus.","date":"2001","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/11298540","citation_count":79,"is_preprint":false},{"pmid":"29526794","id":"PMC_29526794","title":"Role of SARM1 and DR6 in retinal ganglion cell axonal and somal degeneration following axonal injury.","date":"2018","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/29526794","citation_count":68,"is_preprint":false},{"pmid":"11485735","id":"PMC_11485735","title":"Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice.","date":"2001","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11485735","citation_count":64,"is_preprint":false},{"pmid":"7972086","id":"PMC_7972086","title":"Certain HLA-DR5 and -DR6 major histocompatibility complex class II alleles are associated with a CD8 lymphocytic host response to human immunodeficiency virus type 1 characterized by low lymphocyte viral strain heterogeneity and slow disease progression.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7972086","citation_count":56,"is_preprint":false},{"pmid":"19760075","id":"PMC_19760075","title":"Tumor necrosis factor receptor superfamily member 21: TNFR-related death receptor-6, DR6.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/19760075","citation_count":54,"is_preprint":false},{"pmid":"9045685","id":"PMC_9045685","title":"Cloning of the human phospholipase C-gamma1 promoter and identification of a DR6-type vitamin D-responsive element.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9045685","citation_count":50,"is_preprint":false},{"pmid":"23559013","id":"PMC_23559013","title":"A DR6/p75(NTR) complex is responsible for β-amyloid-induced cortical neuron death.","date":"2013","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23559013","citation_count":44,"is_preprint":false},{"pmid":"17257319","id":"PMC_17257319","title":"Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes.","date":"2007","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/17257319","citation_count":34,"is_preprint":false},{"pmid":"24113175","id":"PMC_24113175","title":"Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis.","date":"2013","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24113175","citation_count":29,"is_preprint":false},{"pmid":"21463639","id":"PMC_21463639","title":"The crystal structure of death receptor 6 (DR6): a potential receptor of the amyloid precursor protein (APP).","date":"2011","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21463639","citation_count":24,"is_preprint":false},{"pmid":"9248846","id":"PMC_9248846","title":"HLA-DR6 (possibly DRB1*1301) is associated with susceptibility to Takayasu arteritis in Mexicans.","date":"1996","source":"Heart and vessels","url":"https://pubmed.ncbi.nlm.nih.gov/9248846","citation_count":24,"is_preprint":false},{"pmid":"8883301","id":"PMC_8883301","title":"Six new DR52-associated DRB1 alleles, three of DR8, two of DR11, and one of DR6, reflect a variety of mechanisms which generate polymorphism in the MHC.","date":"1996","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/8883301","citation_count":23,"is_preprint":false},{"pmid":"31189563","id":"PMC_31189563","title":"TNFRSF21 mutations cause high myopia.","date":"2019","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31189563","citation_count":21,"is_preprint":false},{"pmid":"31447828","id":"PMC_31447828","title":"Three Novel Players: PTK2B, SYK, and TNFRSF21 Were Identified to Be Involved in the Regulation of Bovine Mastitis Susceptibility via GWAS and Post-transcriptional Analysis.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31447828","citation_count":21,"is_preprint":false},{"pmid":"26950598","id":"PMC_26950598","title":"Death receptor 6 (DR6) is required for mouse B16 tumor angiogenesis via the NF-κB, P38 MAPK and STAT3 pathways.","date":"2016","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/26950598","citation_count":21,"is_preprint":false},{"pmid":"25838500","id":"PMC_25838500","title":"The crystal structure of DR6 in complex with the amyloid precursor protein provides insight into death receptor activation.","date":"2015","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/25838500","citation_count":21,"is_preprint":false},{"pmid":"29901115","id":"PMC_29901115","title":"Upregulated miR‑20a‑5p expression promotes proliferation and invasion of head and neck squamous cell carcinoma cells by targeting of TNFRSF21.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/29901115","citation_count":20,"is_preprint":false},{"pmid":"33075465","id":"PMC_33075465","title":"Amyloid precursor protein binds with TNFRSF21 to induce neural inflammation in Alzheimer's Disease.","date":"2020","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33075465","citation_count":18,"is_preprint":false},{"pmid":"29459438","id":"PMC_29459438","title":"Non-cell-autonomous function of DR6 in Schwann cell proliferation.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/29459438","citation_count":17,"is_preprint":false},{"pmid":"17254312","id":"PMC_17254312","title":"Prediction of desmoglein-3 peptides reveals multiple shared T-cell epitopes in HLA DR4- and DR6-associated pemphigus vulgaris.","date":"2006","source":"BMC bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/17254312","citation_count":17,"is_preprint":false},{"pmid":"35593591","id":"PMC_35593591","title":"M2 macrophage facilitated angiogenesis in cutaneous squamous cell carcinoma via circ_TNFRSF21/miR-3619-5p/ROCK axis.","date":"2022","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35593591","citation_count":15,"is_preprint":false},{"pmid":"34105277","id":"PMC_34105277","title":"Multi-Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34105277","citation_count":15,"is_preprint":false},{"pmid":"31628183","id":"PMC_31628183","title":"p75NTR and DR6 Regulate Distinct Phases of Axon Degeneration Demarcated by Spheroid Rupture.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31628183","citation_count":14,"is_preprint":false},{"pmid":"8300408","id":"PMC_8300408","title":"DR6 in Koreans. DR11 frequently acts as a recipient gene to create DR13 alleles.","date":"1993","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8300408","citation_count":14,"is_preprint":false},{"pmid":"20053742","id":"PMC_20053742","title":"The DR1 and DR6 first exons of human herpesvirus 6A are not required for virus replication in culture and are deleted in virus stocks that replicate well in T-cell lines.","date":"2010","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/20053742","citation_count":12,"is_preprint":false},{"pmid":"38609388","id":"PMC_38609388","title":"Endothelial DR6 in blood-brain barrier malfunction in Alzheimer's disease.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38609388","citation_count":11,"is_preprint":false},{"pmid":"27579331","id":"PMC_27579331","title":"Association of Immunosuppression with DR6 Expression during the Development and Progression of Spontaneous Ovarian Cancer in Laying Hen Model.","date":"2016","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/27579331","citation_count":10,"is_preprint":false},{"pmid":"23618225","id":"PMC_23618225","title":"Developmental patterns of DR6 in normal human hippocampus and in Down syndrome.","date":"2013","source":"Journal of neurodevelopmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/23618225","citation_count":10,"is_preprint":false},{"pmid":"22567163","id":"PMC_22567163","title":"DR6 as a diagnostic and predictive biomarker in adult sarcoma.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22567163","citation_count":9,"is_preprint":false},{"pmid":"37442735","id":"PMC_37442735","title":"Circ_TNFRSF21 promotes cSCC metastasis and M2 macrophage polarization via miR-214-3p/CHI3L1.","date":"2023","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/37442735","citation_count":8,"is_preprint":false},{"pmid":"31092421","id":"PMC_31092421","title":"Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas.","date":"2019","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31092421","citation_count":8,"is_preprint":false},{"pmid":"34626314","id":"PMC_34626314","title":"Expression of cell proliferation regulatory factors bricd5, tnfrsf21, cdk1 correlates with expression of clock gene cry1 in testes of Hu rams during puberty.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34626314","citation_count":8,"is_preprint":false},{"pmid":"37944567","id":"PMC_37944567","title":"Gene-based association study of rare variants in children of diverse ancestries implicates TNFRSF21 in the development of allergic asthma.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37944567","citation_count":8,"is_preprint":false},{"pmid":"24606703","id":"PMC_24606703","title":"The DR6 protein from human herpesvirus-6B induces p53-independent cell cycle arrest in G2/M.","date":"2014","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/24606703","citation_count":7,"is_preprint":false},{"pmid":"12244201","id":"PMC_12244201","title":"Accelerated onset and increased severity of acute graft-versus-host disease following adoptive transfer of DR6-deficient T cells.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12244201","citation_count":7,"is_preprint":false},{"pmid":"21337622","id":"PMC_21337622","title":"Computational prediction and analysis of the DR6-NAPP interaction.","date":"2011","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/21337622","citation_count":7,"is_preprint":false},{"pmid":"27465898","id":"PMC_27465898","title":"Enhancement of Ovarian Tumor Detection by DR6-Targeted Ultrasound Imaging Agents in Laying Hen Model of Spontaneous Ovarian Cancer.","date":"2016","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/27465898","citation_count":6,"is_preprint":false},{"pmid":"29274771","id":"PMC_29274771","title":"Determination of normal expression patterns of CD86, CD210a, CD261, CD262, CD264, CD358, and CD361 in peripheral blood and bone marrow cells by flow cytometry.","date":"2017","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29274771","citation_count":5,"is_preprint":false},{"pmid":"35654297","id":"PMC_35654297","title":"CCN1 suppresses cell proliferation of esophageal squamous cell carcinoma through amyloid precursor protein without DR6 participation.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35654297","citation_count":4,"is_preprint":false},{"pmid":"39187677","id":"PMC_39187677","title":"LPA suppresses HLA-DR expression in human melanoma cells: a potential immune escape mechanism involving LPAR1 and DR6-mediated release of IL-10.","date":"2024","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/39187677","citation_count":3,"is_preprint":false},{"pmid":"38414449","id":"PMC_38414449","title":"miR-106a mimics the nuclear factor-κB signalling pathway by targeting DR6 in rats with osteoarthritis.","date":"2020","source":"Archives of medical science : AMS","url":"https://pubmed.ncbi.nlm.nih.gov/38414449","citation_count":2,"is_preprint":false},{"pmid":"38478147","id":"PMC_38478147","title":"DR6 Augments Colorectal Cancer Cell Growth, Invasion, and Stemness by Activating AKT/NF-κB Pathway.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38478147","citation_count":1,"is_preprint":false},{"pmid":"40109864","id":"PMC_40109864","title":"Loss of TNFRSF21 induces cisplatin sensitivity in lung adenocarcinoma.","date":"2025","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/40109864","citation_count":1,"is_preprint":false},{"pmid":"42020785","id":"PMC_42020785","title":"The role and mechanism of TNFRSF21 in promoting necroptosis of vascular endothelial cells and inducing vascular leakage in sepsis.","date":"2026","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/42020785","citation_count":0,"is_preprint":false},{"pmid":"41914294","id":"PMC_41914294","title":"TNFRSF21 Orchestrates Epithelial Keratinization and Tight Junction Integrity in Periodontitis-Associated Oral Mucosal Repair.","date":"2026","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/41914294","citation_count":0,"is_preprint":false},{"pmid":"41469311","id":"PMC_41469311","title":"Unraveling the mechanism of alleviating hyperoxia-induced Bronchopulmonary dysplasia: miR-93-5p-mediated regulation of TNFRSF21.","date":"2025","source":"Pediatrics and neonatology","url":"https://pubmed.ncbi.nlm.nih.gov/41469311","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.21.665928","title":"Death receptor 6 does not regulate axon degeneration and Schwann cell injury responses during Wallerian degeneration","date":"2025-07-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.21.665928","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.01.651745","title":"Development and evaluation of screwworm,  <i>Cochliomyia hominivorax</i>  , transgenic sexing strains with embryonic gene promoters for a genetic control program","date":"2025-05-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.01.651745","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.21.619555","title":"RBP4 functions as an antagonistic ligand of orphan DR6","date":"2024-10-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.21.619555","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":30440,"output_tokens":5514,"usd":0.087015,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13993,"output_tokens":5817,"usd":0.107695,"stage2_stop_reason":"end_turn"},"total_usd":0.19471,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"DR6 (TNFRSF21) is a type I transmembrane receptor with four extracellular cysteine-rich motifs and a cytoplasmic death domain. Ectopic expression induces apoptosis and activation of both NF-κB and JNK. DR6 interacts with TRADD (the adaptor previously shown to associate with TNFR1), identified by co-immunoprecipitation.\",\n      \"method\": \"Co-immunoprecipitation, ectopic expression in mammalian cells, apoptosis assays, NF-κB and JNK reporter assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interaction with TRADD shown by Co-IP, functional apoptosis/NF-κB/JNK assays in single study\",\n      \"pmids\": [\"9714541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"DR6-mediated apoptosis is inhibited by Bcl-2, Bcl-xL, and survivin, but a dominant-negative FADD mutant failed to protect against DR6-induced apoptosis, indicating DR6 induces apoptosis via a FADD-independent mechanism. TNF-alpha induces DR6 mRNA and protein expression through NF-κB activation.\",\n      \"method\": \"Dominant-negative FADD co-expression, Bcl-2/Bcl-xL overexpression rescue assays, TNF-alpha treatment with NF-κB inhibitors, RT-PCR and western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined pathway placement (FADD-independent), NF-κB-dependent transcriptional regulation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"11753679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"DR6 is highly expressed in resting T cells and downregulated upon activation. DR6-deficient mice show hyperproliferation of CD4+ T cells in response to TCR stimulation and protein antigen challenge, enhanced IL-2 responsiveness, increased CD28 and decreased CTLA-4 expression, and enhanced Th2 cytokine production associated with increased nuclear NF-ATc. DR6 thus functions as a negative regulatory receptor for CD4+ T cell activation.\",\n      \"method\": \"DR6 knockout mouse generation, T cell proliferation assays, cytokine measurement, flow cytometry, transcription factor nuclear localization assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse with specific T cell phenotype, multiple orthogonal readouts including proliferation, cytokine profiling, and signaling molecule quantification\",\n      \"pmids\": [\"11485735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DR6 is broadly expressed by developing neurons and is required for normal cell body death (via caspase 3) and axonal pruning (via caspase 6) after trophic-factor deprivation. Trophic-factor deprivation triggers BACE-dependent shedding of surface APP, releasing an N-terminal APP fragment (N-APP) that binds DR6 and triggers degeneration. Loss- and gain-of-function studies in vitro and in vivo, plus a common neuromuscular junction phenotype in APP and DR6 mutant mice, support this model.\",\n      \"method\": \"Loss-of-function (DR6 KO mice, siRNA), gain-of-function, binding assays (N-APP/DR6 interaction), caspase activity assays, in vivo axon pruning/neuron death assays, genetic epistasis (NMJ phenotype in double mutant mice)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including KO mouse, in vitro binding, caspase-specific assays, and genetic epistasis; replicated in multiple experimental systems\",\n      \"pmids\": [\"19225519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of the extracellular cysteine-rich region of DR6 resolved to 2.2 Å, showing four cysteine-rich domains (CRDs) arranged in a rod-like structure with DR6-specific surface patches responsible for ligand recognition.\",\n      \"method\": \"X-ray crystallography of recombinant DR6 extracellular domain\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure at 2.2 Å resolution, single study but rigorous structural method\",\n      \"pmids\": [\"21463639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"DR6 and TROY (TNFRSF19) interact both genetically and physically, are required for VEGF-mediated JNK activation and human brain endothelial sprouting in vitro, and regulate CNS-specific angiogenesis and blood-brain barrier formation. DR6 and TROY are downstream target genes of Wnt/β-catenin signaling in brain endothelium.\",\n      \"method\": \"Co-immunoprecipitation (DR6/TROY physical interaction), zebrafish and mouse genetic knockouts, in vitro endothelial sprouting assays, JNK activity assays, gene expression profiling\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction demonstrated, genetic epistasis in two model organisms, in vitro functional assays with defined signaling readout\",\n      \"pmids\": [\"22340501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DR6 binds p75NTR and forms a signaling complex responsible for Aβ-induced cortical neuron death. Cortical neurons from DR6 or p75NTR null mice are resistant to Aβ-induced neurotoxicity. Blocking DR6/p75NTR interaction with anti-DR6 antibodies or dominant-negative DR6 (lacking the cytoplasmic death domain) attenuates caspase 3 activation and cell death.\",\n      \"method\": \"Co-immunoprecipitation (DR6/p75NTR complex), DR6 and p75NTR null mouse neurons, dominant-negative DR6 construct, anti-DR6 blocking antibodies, caspase 3 activity assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, two independent KO mouse lines, dominant-negative rescue, multiple orthogonal functional assays in single study\",\n      \"pmids\": [\"23559013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of DR6 ectodomain in complex with the E2 domain of APP, showing the structural basis of APP binding to DR6 and supporting a model in which APP induces DR6 dimerization and activation at the cell surface.\",\n      \"method\": \"X-ray crystallography of DR6 ectodomain/APP-E2 complex\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure of the complex providing direct structural evidence for the interaction mechanism, single study\",\n      \"pmids\": [\"25838500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-210 targets the 3'-UTR of DR6 to inhibit its expression (confirmed by luciferase assay), thereby inhibiting NF-κB pathway activation and reducing inflammatory cytokine production and apoptosis in chondrocytes.\",\n      \"method\": \"Luciferase reporter assay (miR-210 targeting DR6 3'-UTR), miR-210 mimic/siDR6 transfection, NF-κB pathway activation assays, cytokine ELISA\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — luciferase reporter validates direct miRNA targeting, NF-κB pathway readout provided, single lab\",\n      \"pmids\": [\"26244598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DR6 knockdown in mouse B16 melanoma cells suppresses tumor angiogenesis in vivo by inhibiting IL-6 secretion, which in turn reduces VEGF-A, PDGF-β, VEGF-D, and PDGFR-α expression. DR6-dependent angiogenesis proceeds through IL-6/P38 MAPK and IL-6/STAT3 pathways.\",\n      \"method\": \"DR6 knockdown in B16 cells, xenograft tumor model, cytokine profiling, pathway inhibitor assays (P38 MAPK, STAT3)\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo xenograft with mechanistic pathway dissection, single lab\",\n      \"pmids\": [\"26950598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Neuronal DR6 is cleaved by ADAM10, releasing a soluble DR6 ectodomain (sDR6) that acts in a non-cell-autonomous (paracrine) manner to reduce Schwann cell proliferation and myelination. This function is independent of DR6's cytoplasmic death domain. The sDR6 ectodomain alone was sufficient to rescue the precocious myelination phenotype observed in DR6 KO mice.\",\n      \"method\": \"DR6 KO mice, in vitro myelination assay, ADAM10 cleavage identification (proteomics/biochemistry), sDR6 rescue experiment, death domain deletion construct\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse phenotype, identification of ADAM10 as sheddase, domain deletion construct, and sDR6 rescue in a single study with multiple orthogonal methods\",\n      \"pmids\": [\"29459438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DR6, but not p75NTR, is required for transition into the catastrophic phase of axon degeneration in response to conditioned media from degenerating axons following trophic withdrawal. DR6 acts downstream of spheroid rupture and is calpain-dependent in this process, but is not required for intra-axonal calcium flux, spheroid formation, or spheroid rupture.\",\n      \"method\": \"DR6 KO mouse neurons, conditioned media transfer assay, live imaging of axon degeneration phases, calpain inhibitor assays\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DR6 KO neurons with defined phased degeneration assay, single lab\",\n      \"pmids\": [\"31628183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"APP and TNFRSF21 interact at the protein level (confirmed by Co-IP) in AD model mice. TNFRSF21 knockdown reduces APP expression and decreases neuroinflammation (TNF-α, IL-5, IFN-γ levels) and neuronal apoptosis in transgenic AD mice.\",\n      \"method\": \"Co-immunoprecipitation, TNFRSF21 knockdown in vitro, ELISA for inflammatory cytokines, flow cytometry for apoptosis, immunofluorescence\",\n      \"journal\": \"European journal of pharmaceutical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP confirms interaction, knockdown with functional inflammatory readouts, single lab\",\n      \"pmids\": [\"33075465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"APP expressed on tumor cells binds DR6 on vascular endothelial cells to initiate the necroptosis pathway, leading to endothelial cell death and tumor cell extravasation/metastasis. A peptidomimetic inhibitor of DR6/APP interaction (PEG-tAHP-DRI, KD = 51.12 nM) blocked TC-induced EC necroptosis in vitro and anti-hematogenous metastasis in multiple mouse models.\",\n      \"method\": \"Phage display-derived peptidomimetic binding assay (KD measurement), in vitro necroptosis assay, multiple in vivo metastatic mouse models (B16F10, 4T1, CT26)\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantified binding affinity, multiple in vivo models confirm necroptosis pathway activation, single lab\",\n      \"pmids\": [\"34105277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Suppression of endothelial DR6 results in blood-brain barrier malfunction in the presence of Aβ oligomers, while DR6 overexpression in brain endothelial cells increases BBB functional proteins through activation of Wnt/β-catenin and JNK pathways and rescues BBB dysfunction in vitro.\",\n      \"method\": \"DR6 knockdown/overexpression in cultured brain endothelial cells, Aβ25-35 oligomer treatment, western blot for BBB functional proteins and pathway activation (Wnt/β-catenin, JNK), in vitro BBB permeability assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with defined signaling pathway readouts, single lab\",\n      \"pmids\": [\"38609388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DR6 knockdown in colorectal cancer cells reduces AKT and NF-κB phosphorylation, and treatment with AKT activator SC79 rescues the inhibitory effects of DR6 knockdown on proliferation, migration, invasion, and stemness, establishing DR6 as an upstream activator of the AKT/NF-κB pathway in CRC.\",\n      \"method\": \"DR6 knockdown/overexpression, CCK-8 proliferation assay, transwell assays, sphere-forming assays, western blot for p-AKT and p-NF-κB, AKT activator rescue experiment, nude mouse xenograft\",\n      \"journal\": \"Biochemical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis rescue with SC79 places DR6 upstream of AKT/NF-κB, in vivo xenograft confirmation, single lab\",\n      \"pmids\": [\"38478147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RBP4 (retinol binding protein 4) was identified as an antagonistic ligand of DR6. RBP4 drives DR6 dimerization on the plasma membrane via an extracellular intrinsically disordered region, preventing DR6 pro-degenerative heterointeractions and neurodegenerative processes. DR6 homodimerization is Ca2+-sensitive and depends on the extracellular intrinsically disordered region.\",\n      \"method\": \"Single-molecule photobleaching, single-receptor tracking, RBP4-DR6 binding characterization, domain deletion/mutation analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single-molecule methods are rigorous, but preprint and single lab without independent replication\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TNFRSF21 promotes necroptosis of vascular endothelial cells in sepsis by upregulating RIPK3 and phospho-MLKL (necrosome components). shTNFRSF21 inhibited necrosome (RIPK3/p-MLKL) formation in septic vascular endothelial cells, improved vascular leakage in septic rats, and prolonged survival.\",\n      \"method\": \"shTNFRSF21 knockdown, western blot for RIPK3/p-MLKL, CLP and LPS sepsis models in vivo, vascular leakage assays, necroptosis inhibitor treatment\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo sepsis model with defined pathway (RIPK1/RIPK3/MLKL necrosome), multiple readouts, single lab\",\n      \"pmids\": [\"42020785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"TNFRSF21 interacts with APP (confirmed by immunoprecipitation) in keratinocytes and regulates epithelial keratinization: TNFRSF21 knockdown downregulates KRT8, KRT18, and Claudin-1, while overexpression upregulates them and accelerates wound healing in a mouse model.\",\n      \"method\": \"Co-immunoprecipitation (TNFRSF21/APP interaction), gene knockdown and overexpression in keratinocytes, bulk RNA-seq, PPI analysis, full-thickness dorsal skin wound mouse model, immunostaining\",\n      \"journal\": \"Frontiers in bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirms interaction, KD/OE with defined keratinization phenotype, in vivo wound model, single lab\",\n      \"pmids\": [\"41914294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Transfer of DR6 KO T cells into allogeneic recipients accelerates onset and increases severity of acute graft-versus-host disease, demonstrating that DR6 serves as a negative regulatory molecule in T cell immune responses in vivo. Enhanced activation and expansion of DR6 KO CD4+ and CD8+ T cells was observed.\",\n      \"method\": \"Adoptive transfer of DR6 KO T cells in parent-to-F1 GVHD model, histopathological analysis, T cell expansion quantification\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo adoptive transfer with defined cellular and histopathological phenotype, single lab\",\n      \"pmids\": [\"12244201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DR6 promotes motor neuron death in ALS through activation of the caspase 3 signaling pathway. Blocking DR6 with antagonist antibody 5D10 promotes motor neuron survival via activation of Akt phosphorylation and inhibition of caspase 3, in growth factor withdrawal, arsenite treatment, and SOD1(G93A) astrocyte co-culture models.\",\n      \"method\": \"DR6 antagonist antibody treatment, caspase 3 activity assays, Akt phosphorylation western blot, in vitro motor neuron survival assays, SOD1(G93A) transgenic mouse treatment\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro stress models plus in vivo transgenic mouse, defined caspase 3/Akt pathway, single lab\",\n      \"pmids\": [\"24113175\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF21/DR6 is a death domain-containing TNF receptor superfamily member that functions as a context-dependent signaling hub: its extracellular domain binds APP (N-terminal fragment) and RBP4 to regulate neuronal axon pruning and cell body death via caspase 6 and caspase 3 respectively, forms a complex with p75NTR to mediate Aβ-induced neurotoxicity, is shed by ADAM10 to generate a soluble ectodomain that non-cell-autonomously controls Schwann cell proliferation/myelination, activates JNK and NF-κB signaling to regulate CNS angiogenesis/BBB integrity (partnering with TROY downstream of Wnt/β-catenin), acts as a negative regulator of T cell activation (limiting CD4+ proliferation and Th2 cytokine responses), promotes tumor angiogenesis through IL-6/STAT3/P38 MAPK pathways, drives necroptosis (RIPK3/p-MLKL) in vascular endothelial cells during sepsis, and activates the AKT/NF-κB pro-survival pathway in cancer cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFRSF21 (DR6) is a type I transmembrane death-domain receptor of the TNF receptor superfamily that acts as a context-dependent signaling hub coupling extracellular ligand engagement to apoptosis, inflammation, and developmental remodeling [#0, #3]. Its ectodomain comprises four cysteine-rich domains arranged in a rod-like structure with receptor-specific surface patches for ligand recognition [#4], and it is activated at the cell surface by ligand-induced dimerization: an N-terminal fragment of APP binds the DR6 ectodomain and drives dimerization [#3, #7], while RBP4 acts as an antagonistic ligand that forces a non-productive Ca2+-sensitive homodimer and blocks pro-degenerative heterointeractions [#16]. Engaged DR6 signals through a FADD-independent route to activate NF-\\u03baB and JNK and to trigger apoptosis [#0, #1]; in developing neurons it executes trophic-deprivation degeneration by directing caspase-3-mediated cell-body death and caspase-6-mediated axon pruning, acting downstream of axonal spheroid rupture in a calpain-dependent manner [#3, #11]. DR6 partners with p75NTR to mediate A\\u03b2-induced cortical neuron death [#6] and with TROY downstream of Wnt/\\u03b2-catenin to drive VEGF-dependent JNK activation, CNS angiogenesis, and blood-brain-barrier formation [#5, #14]. ADAM10 sheds the receptor to release a soluble ectodomain that acts non-cell-autonomously to restrain Schwann cell proliferation and myelination, independent of the cytoplasmic death domain [#10]. In the immune system DR6 is a negative regulator of CD4+ T cell activation, limiting proliferation and Th2 cytokine responses and constraining graft-versus-host disease [#2, #19]. In pathological vascular and tumor settings it promotes endothelial necroptosis via RIPK3/p-MLKL and tumor angiogenesis through IL-6/STAT3/p38 MAPK signaling [#13, #17, #9], and in carcinoma cells it activates an AKT/NF-\\u03baB pro-survival program [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established DR6 as a death-domain TNFR superfamily receptor that couples to canonical inflammatory and stress signaling, answering what kind of receptor this orphan was.\",\n      \"evidence\": \"Co-IP, ectopic expression and reporter assays in mammalian cells\",\n      \"pmids\": [\"9714541\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No physiological ligand identified\", \"TRADD interaction not placed in a downstream effector pathway\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the apoptotic wiring of DR6 as FADD-independent and showed its expression is induced by TNF-\\u03b1 via NF-\\u03baB, clarifying both how it kills and how it is transcriptionally controlled.\",\n      \"evidence\": \"Dominant-negative FADD, Bcl-2/Bcl-xL rescue, NF-\\u03baB inhibitor and RT-PCR/western assays\",\n      \"pmids\": [\"11753679\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the FADD-independent adaptor unresolved\", \"Apoptotic mechanism studied only in overexpression\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Revealed an unanticipated immunological role: DR6 negatively regulates CD4+ T cell activation, expanding its function beyond apoptosis.\",\n      \"evidence\": \"DR6 KO mouse, proliferation/cytokine/transcription-factor assays\",\n      \"pmids\": [\"11485735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand mediating T cell suppression not defined\", \"Intracellular signaling linking DR6 to NF-ATc not mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Confirmed the negative-regulatory role of DR6 in vivo, showing loss accelerates graft-versus-host disease.\",\n      \"evidence\": \"Adoptive transfer of DR6 KO T cells in parent-to-F1 GVHD model\",\n      \"pmids\": [\"12244201\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-intrinsic versus extrinsic basis of the phenotype not separated\", \"No ligand identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified N-APP as a DR6 ligand and assigned DR6 distinct caspase routes for cell-body death (caspase 3) versus axon pruning (caspase 6) during trophic deprivation, providing the first ligand and developmental mechanism.\",\n      \"evidence\": \"DR6 KO/siRNA, binding assays, caspase-specific assays, NMJ genetic epistasis with APP mutants\",\n      \"pmids\": [\"19225519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism segregating caspase-3 vs caspase-6 outputs unknown\", \"Proximal cytoplasmic signaling adaptor undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided the structural framework for DR6 ligand recognition by resolving its four-CRD ectodomain.\",\n      \"evidence\": \"X-ray crystallography of recombinant DR6 ectodomain at 2.2 \\u00c5\",\n      \"pmids\": [\"21463639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ligand bound in this structure\", \"Activation-associated conformational changes not captured\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed DR6 in a TROY-containing complex downstream of Wnt/\\u03b2-catenin that drives CNS angiogenesis and BBB formation via VEGF-dependent JNK, defining a developmental vascular function.\",\n      \"evidence\": \"Co-IP, zebrafish and mouse knockouts, endothelial sprouting and JNK assays, expression profiling\",\n      \"pmids\": [\"22340501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand triggering endothelial DR6/TROY signaling unknown\", \"Stoichiometry of the DR6/TROY complex undefined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed DR6 forms a complex with p75NTR to mediate A\\u03b2-induced cortical neuron death, linking it to amyloid neurotoxicity.\",\n      \"evidence\": \"Reciprocal Co-IP, DR6 and p75NTR null neurons, dominant-negative and blocking antibody, caspase 3 assays\",\n      \"pmids\": [\"23559013\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether A\\u03b2 binds DR6 directly not established\", \"Relationship between p75NTR and APP ligand pathways unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended DR6-driven death to motor neurons in ALS and showed antagonist antibody promotes survival via Akt/caspase-3, indicating therapeutic tractability.\",\n      \"evidence\": \"Antagonist antibody 5D10, caspase 3 and Akt assays, multiple stress models and SOD1(G93A) mice\",\n      \"pmids\": [\"24113175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous ligand in ALS models not identified\", \"Antibody mechanism of action not structurally defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the structural basis of APP-induced activation by resolving the DR6 ectodomain/APP-E2 complex and supporting a dimerization model.\",\n      \"evidence\": \"X-ray crystallography of DR6 ectodomain/APP-E2 complex\",\n      \"pmids\": [\"25838500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Higher-order receptor clustering not visualized\", \"Coupling of dimerization to cytoplasmic signaling not shown structurally\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified miR-210 as a post-transcriptional repressor of DR6 that dampens NF-\\u03baB-driven inflammation, adding a regulatory input layer.\",\n      \"evidence\": \"Luciferase 3'-UTR reporter, miR-210 mimic/siDR6, NF-\\u03baB and cytokine assays in chondrocytes\",\n      \"pmids\": [\"26244598\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality of miR-210 control beyond chondrocytes untested\", \"In vivo relevance not demonstrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked DR6 to tumor angiogenesis through IL-6/STAT3 and IL-6/p38 MAPK control of pro-angiogenic factors.\",\n      \"evidence\": \"DR6 knockdown in B16 cells, xenograft, cytokine profiling, pathway inhibitors\",\n      \"pmids\": [\"26950598\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor-proximal events upstream of IL-6 not defined\", \"Single tumor model\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed a non-cell-autonomous mechanism: ADAM10 sheds DR6 to release a soluble ectodomain that restrains Schwann cell myelination independent of the death domain.\",\n      \"evidence\": \"DR6 KO mice, ADAM10 cleavage mapping, sDR6 rescue and death-domain deletion construct, myelination assays\",\n      \"pmids\": [\"29459438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor/target of sDR6 on Schwann cells unknown\", \"Regulation of ADAM10 cleavage not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Positioned DR6 at the catastrophic transition of axon degeneration, downstream of spheroid rupture and calpain-dependent, refining its temporal role.\",\n      \"evidence\": \"DR6 KO neurons, conditioned-media transfer, live imaging, calpain inhibitors\",\n      \"pmids\": [\"31628183\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Diffusible factor in conditioned media not identified\", \"Link between calpain and DR6 activation unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Reinforced DR6/APP interaction and showed DR6 knockdown reduces APP expression, neuroinflammation, and apoptosis in AD model mice.\",\n      \"evidence\": \"Co-IP, knockdown, cytokine ELISA, apoptosis flow cytometry\",\n      \"pmids\": [\"33075465\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Directionality of DR6-APP regulation not mechanistically resolved\", \"Single AD model\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated tumor-cell APP engages endothelial DR6 to trigger necroptosis enabling metastasis, and that blocking the interaction is anti-metastatic.\",\n      \"evidence\": \"Peptidomimetic binding (KD 51 nM), in vitro necroptosis, multiple metastasis mouse models\",\n      \"pmids\": [\"34105277\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking DR6 to RIPK3/MLKL necrosome not detailed here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed endothelial DR6 maintains BBB integrity against A\\u03b2 oligomers through Wnt/\\u03b2-catenin and JNK, connecting its vascular and amyloid roles.\",\n      \"evidence\": \"DR6 knockdown/overexpression in brain endothelial cells, A\\u03b2 treatment, pathway western blots, permeability assay\",\n      \"pmids\": [\"38609388\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo BBB confirmation absent\", \"Ligand driving protective signaling unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established DR6 as an upstream activator of AKT/NF-\\u03baB driving proliferation, invasion, and stemness in colorectal cancer.\",\n      \"evidence\": \"Knockdown/overexpression, SC79 rescue, functional assays, xenograft\",\n      \"pmids\": [\"38478147\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor-proximal coupling to AKT undefined\", \"Ligand in CRC context unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified RBP4 as an antagonistic ligand that drives Ca2+-sensitive DR6 homodimerization via an extracellular disordered region to block pro-degenerative heterointeractions, reframing dimerization state as the activity switch.\",\n      \"evidence\": \"Single-molecule photobleaching, single-receptor tracking, domain mutation analysis (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, single lab, not independently replicated\", \"In vivo neuroprotection by RBP4 not shown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed TNFRSF21 promotes endothelial necroptosis in sepsis by upregulating the RIPK3/p-MLKL necrosome, extending its necroptotic role to systemic vascular injury.\",\n      \"evidence\": \"shTNFRSF21, RIPK3/p-MLKL western blots, CLP and LPS sepsis models, survival/leakage assays\",\n      \"pmids\": [\"42020785\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link from DR6 to necrosome assembly not defined\", \"Activating ligand in sepsis unknown\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Revealed a non-neuronal epithelial function: TNFRSF21 interacts with APP and regulates keratinization genes and wound healing.\",\n      \"evidence\": \"Co-IP, knockdown/overexpression in keratinocytes, RNA-seq, wound-healing mouse model\",\n      \"pmids\": [\"41914294\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway linking DR6 to keratin genes not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ligand-driven dimerization state (productive APP-induced vs antagonistic RBP4-induced) is decoded into divergent outputs\\u2014apoptosis, necroptosis, NF-\\u03baB/JNK, AKT survival\\u2014through a defined cytoplasmic adaptor remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"FADD-independent proximal adaptor unidentified\", \"Mechanism selecting caspase-3 vs caspase-6 vs RIPK3 outputs unknown\", \"No unified model reconciling pro-death and pro-survival roles across cell types\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 6, 7]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [3, 7, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 10, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 7, 10, 16]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 6, 13, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 9, 14, 15]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 5, 10]}\n    ],\n    \"complexes\": [\n      \"DR6/p75NTR signaling complex\",\n      \"DR6/TROY complex\"\n    ],\n    \"partners\": [\n      \"APP\",\n      \"TRADD\",\n      \"p75NTR\",\n      \"TROY\",\n      \"RBP4\",\n      \"ADAM10\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}